Wire · operational-macro
US FDA Approves Sun Pharmaceutical ILUMYA for Adults with Active Psoriatic Arthritis
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
The US FDA has approved Sun Pharmaceutical's ILUMYA (tildrakizumab-asmn) for treating adults with active psoriatic arthritis, expanding its prior approval for plaque psoriasis. The approval is based on Phase 3 clinical trials demonstrating safety and efficacy, offering a healthcare professional-administered treatment option.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
The FDA approval opens a direct sales channel for you in US psoriatic arthritis care through healthcare-administered biologics, favouring treatments delivered by clinics over self-injection. You need to focus on establishing relations with rheumatology providers who prefer clinic-controlled administration.
◆ Coverage
2 sources · 2 Nov 2026
◆ Related on Wire
◆ Topics